MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel

J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, S. Bataga, R. Neagoe, J. Szederjesi, B. Grigorescu, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari (Targu Mures, Romania)

Meeting: 2022 International Congress

Abstract Number: 1047

Keywords: Dopamine agonists, Levodopa(L-dopa), Parkinson’s

Category: Parkinson’s Disease: Pharmacology and Therapy

Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients with advanced Parkinson’s Disease (APD), treated with Levodopa Carbidopa Intestinal Gel (LCIG).

Background: Background: DA can be used in every stage of PD, even in APD (as an add-on therapy with time-limited efficacy). Continuous intra-jejunal infusion of LCIG is a long-term proven and effective treatment in APD with severe motor fluctuations, with or without dyskinesias.

Method: Methods: We performed a retrospective review of all APD patients treated with LCIG between June 2011 and June 2021 at the 2nd Department of Neurology in Târgu Mureş. We analyzed the usage of dopaminergic agents, based on the last treatment recommendations and referral letters.

Results: Results: Treatment with LCIG was initiated in 150 patients with APD (81 men, 69 women) with an average age of 63.97±8.2 years (mean±SD) and an average disease duration of 10.95±4.4 years. The mean treatment duration with Levodopa was 10.59±4.4 years with an average daily dose of 854.16±258.15 mg, divided into 5.18±0.97 doses. Most patients (123, 82%) also had treatment with dopamine agonists, namely Pramipexole in 42 cases (average dose 2.3±0.6 mg), Ropinirole in 33 patients (average dose 13.45±4.93 mg) or Rotigotine patch in 51 cases (average dose 8.16±2.92 mg). In three cases the combination of two dopamine agonists was used (Rotigotine as an add-on option). In the evaluated period, apomorphine was not available. All patients had off periods with an average duration of 4.73±1.08 hours daily and 95 patients also had dyskinesias (2.96±0.84 hours/day).

Conclusion: Conclusions: In our department, just before initiating LCIG treatment, the frequency of levodopa usage was adequate while the average daily dose was at the lower end found in the literature, whereas the combination with dopamine agonists was more common/higher. We consider that the decision-making process and the therapeutic strategy are more difficult and limited if there is no access to all adjuvant dopaminergic drugs or DATs.

To cite this abstract in AMA style:

J. Szasz, V. Constantin, K. Orban-Kis, L. Bancu, S. Bataga, R. Neagoe, J. Szederjesi, B. Grigorescu, M. Ciorba, I. Mihaly, K. Kelemen, S. Szatmari. Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/dopamine-agonist-utilization-prior-to-the-initiation-of-device-aided-therapy-data-from-150-patients-with-advanced-parkinsons-disease-treated-with-levodopa-carbidopa-intestinal-gel/. Accessed May 15, 2025.
  • Tweet
  • Email
  • Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/dopamine-agonist-utilization-prior-to-the-initiation-of-device-aided-therapy-data-from-150-patients-with-advanced-parkinsons-disease-treated-with-levodopa-carbidopa-intestinal-gel/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Yerba Mate (Ilex paraguaiensis) protects dopaminergic neurons degeneration and improve their maturation in culture
  • #26133 (not found)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley